|
| Status |
Public on Jun 26, 2024 |
| Title |
PT24-MT Cycle 1 Day 8 |
| Sample type |
SRA |
| |
|
| Source name |
whole blood
|
| Organism |
Homo sapiens |
| Characteristics |
tissue: whole blood
treatment time point: MT Cycle 1 Day 8
dose cohort: 275
c1d1 cpi-0209 exposure: 798
patient: PT24
|
| Treatment protocol |
The patients were from the phase 1 portion of the phase 1/2 study of CPI-0209 in patients with advanced tumors (clinicaltrials.gov identifier: NCT04104776). Phase 1 was a 7-cohort dose escalation study in patients receiving CPI-0209 once daily at doses between 50 and 375 mg. All patients gave informed consent and the trial was conducted in accordance with the Declaration of Helsinki.
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Whole blood cells were collected using PAXgene blood RNA tubes. Proccessing and sequencing of patient RNA samples were performed by ALMAC. The RNA extractions were performed using PAXgene Blood RNA Kit following manufacturer’s instructions.
Library preparation proceeded with rRNA and hemoglobin depletion using KAPA RNA HyperPrep Kit with RiboErase (HMR) Globin. Paired-end 75 base pair sequencing was performed on an Illumina platform. Prior to sequencing, RNA integrity was assessed by 2100 Bioanalyser (Agilent) and concentration was assayed by Nanodrop.
|
| |
|
| Library strategy |
RNA-Seq |
| Library source |
transcriptomic |
| Library selection |
cDNA |
| Instrument model |
Illumina HiSeq 4000 |
| |
|
| Data processing |
Sequencing reads were mapped to the genome using STAR v2.7.3a with default settings
The transcript and gene read count quantification were performed using RSEM v1.3.1 with default settings
Genome_build: hg38
|
| |
|
| Submission date |
Jun 09, 2021 |
| Last update date |
Jun 26, 2024 |
| Contact name |
Patrick Trojer |
| E-mail(s) |
patricktroj@gmail.com
|
| Organization name |
Constellation Pharmaceuticals
|
| Street address |
215 First Street, Suite 200
|
| City |
Cambridge |
| State/province |
Massachusetts |
| ZIP/Postal code |
02142 |
| Country |
USA |
| |
|
| Platform ID |
GPL20301 |
| Series (2) |
| GSE176490 |
Study of CPI-0209 in patients with advanced tumors. |
| GSE176493 |
Comprehensive target engagement by EZH2 inhibitor CPI-0209 allows for preferential targeting of ARID1A mutant urothelial carcinoma |
|
| Relations |
| BioSample |
SAMN19644562 |
| SRA |
SRX11101691 |
